Lessons from a community vaccination programme to control a meningococcal disease serogroup W outbreak in remote South Australia, 2017.


Journal

Western Pacific surveillance and response journal : WPSAR
ISSN: 2094-7313
Titre abrégé: Western Pac Surveill Response J
Pays: Philippines
ID NLM: 101558993

Informations de publication

Date de publication:
Historique:
entrez: 7 6 2021
pubmed: 8 6 2021
medline: 4 8 2021
Statut: epublish

Résumé

From December 2016 to February 2017, two cases of invasive meningococcal disease and one case of meningococcal conjunctivitis, all serogroup W, occurred in Aboriginal children in the Ceduna region of South Australia. The clustering of cases in time and place met the threshold for a community outbreak. The Ceduna region is a remote part of South Australia, with more than 25% of the population identifying as Aboriginal or Torres Strait Islander. As part of the outbreak response, a community-wide meningococcal vaccination programme against serogroups A, C, W and Y was implemented in a collaboration among different agencies of the South Australia Department for Health and Well-being, Aboriginal health and community services providers, and other local service providers and government agencies. The programme comprised an outbreak vaccination schedule, targeting all people aged Between March and June 2017, 3383 persons were vaccinated, achieving an estimated coverage of 71-85% of the target population, with 31% ( The participation of a large number of local and non-health-sector stakeholders in programme planning and implementation, a clear response management structure and high community acceptability were identified as key factors that contributed to the programme achieving high vaccination coverage. The need to develop standard operating procedures for community-based outbreak response interventions to ease logistical challenges was considered an important lesson learnt.

Identifiants

pubmed: 34094620
doi: 10.5365/wpsar.2019.10.2.002
pii: wpsar.2021.12.1-026
pmc: PMC8143929
doi:

Substances chimiques

Meningococcal Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-31

Informations de copyright

(c) 2021 The authors; licensee World Health Organization.

Références

N Engl J Med. 2001 May 3;344(18):1378-88
pubmed: 11333996
Vaccine. 2019 May 9;37(21):2768-2782
pubmed: 30987851
BMJ Open. 2018 Jul 10;8(7):e020988
pubmed: 29991629
Euro Surveill. 2016;21(12):
pubmed: 27035055
Lancet Infect Dis. 2010 Dec;10(12):853-61
pubmed: 21075057
Vaccine. 2014 Apr 11;32(18):2042-9
pubmed: 24593997

Auteurs

Louise Flood (L)

Communicable Disease Control Branch, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Matthew McConnell (M)

Country Health SA Local Health Network, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Luda Molchanoff (L)

Country Health SA Local Health Network, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Zell Dodd (Z)

Ceduna Koonibba Aboriginal Health Service, Ceduna, South Australia, Australia.

Jana Sisnowski (J)

Communicable Disease Control Branch, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Melissa Fidock (M)

Communicable Disease Control Branch, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Tina Miller (T)

Ceduna Koonibba Aboriginal Health Service, Ceduna, South Australia, Australia.

Karli Borresen (K)

Media and Communications Branch, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Hannah Vogt (H)

Communicable Disease Control Branch, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Andrew Lane (A)

Country Health SA Local Health Network, South Australia Department for Health and Wellbeing, Adelaide, South Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH